Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer

Beaumont Hospital40 enrolled

Overview

This is a prospective, non-interventional, single arm study, which is examining doxorubicin and cyclophosphamide (AC) once every 2 weeks with lipegfilgrastim support in early breast cancer.

An important advance in the use of dose dense chemotherapy regimens for breast cancer was the development of pegylated form of G-CSF (pegfilgrastim and lipegfilgrastim), which offered the convenience of single subcutaneous injection, rather than multiple daily injections Lipegfilgrastim is a pegylated long-acting covalent conjugate of filgrastim (G-CSF). In a pivotal randomized phase III study in breast cancer lipegfilgrastim was shown to be non-inferior to pegfilgrastim. In this prospective observational study the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support is being investigated. Data will be collected on 40 consecutive patients treated with AC and lipegfilgrastim in Ireland. The primary objective of this study is to determine the incidence of treatment-related neutropenia following four cycles of dose dense doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks). Secondary Objectives 1. Determine the incidence of febrile neutropenia during 4 cycles (8 weeks)of dose dense AC with lipegfilgrastim 2. Examine the incidence of treatment-related neutropenia during subsequent intravenous cancer therapy up to 1 year.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Interventions

LipegfilgrastimDRUG

Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥ 18 years 2. Stage I-III Breast Cancer 3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1(see below) 4. Adequate Bone Marrow Function as defined by neutrophil count of ≥1.0 and platelet count of ≥ 100 5. Planned chemotherapy with Dose Dense Doxorubicin-Cyclophosphamide (AC) as deemed appropriate by a Consultant Medical Oncologist General Indications for Dose Dense AC include: 1. T3 or T4 Tumours 2. N1 - N3 (Node Positive) Disease 3. Human Epidermal Growth Factor Receptor 2 (HER2) Positive Tumours. 4. Triple Negative Breast Cancer as evidenced by lack of expression of the estrogen receptor (ER), progesterone receptor (PR) and HER2 Exclusion Criteria: 1. Stage IV Breast Cancer 2. Pregnancy 3. Previous Chemotherapy Exposure 4. Prior Exposure to G-CSF 5. Known positive HIV Status 6. Cardiac or other concurrent illness, which at the investigator's discretion contraindicates the use of AC

Locations (1)

Beaumont Hospital

Dublin, Ireland

Outcomes

Primary Outcomes

incidence of treatment-related neutropenia

The primary objective of this study is to determine the incidence of treatment-related neutropenia following four cycles of dose dense doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).

Time frame: four cycles of dose dense doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).

Secondary Outcomes

incidence of febrile neutropenia

Determine the incidence of febrile neutropenia during 4 cycles (8 weeks) of dose dense AC with lipegfilgrastim

Time frame: four cycles of dose dense doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).

incidence of treatment-related neutropenia

Determine the incidence of treatment-related neutropenia during subsequent chemotherapy (up to 1 year)

Time frame: Up to 1 year of subsequent chemotherapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.